Drug or treatment
Tepotinib clinical trials
As of November 12, 2026, Find a Trial lists 4 clinical trials of Tepotinib that are recruiting, at sites in 3 countries (most in United States (2), South Korea (1), France (1)). By phase: Phase 2 (2), Phase 3 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 3Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Tepotinib plus Ivonescimab for MET exon 14–positive NSCLC | Phase 1 | Basking Ridge, New Jersey and 6 other locations | Recruiting | Jun 2, 2026 |
| Tepotinib versus standard treatments for advanced MET exon 14–mutated non-small cell lung cancer after prior therapy | Phase 3 | Besançon and 28 other locations | Recruiting | Apr 3, 2025 |
| Adding tepotinib to lazertinib for EGFR‑mutant metastatic lung cancer with MET overexpression or amplification after progression on lazertinib | Phase 2 | Seoul, Gangnam-gu | Recruiting | Oct 30, 2023 |
| Targeted treatment for advanced lung cancer with a specific gene change | Phase 2 | Daphne, Alabama and 277 other locations | Recruiting | Sep 11, 2023 |
All recruiting trials (4)
-
Tepotinib plus Ivonescimab for MET exon 14–positive NSCLC
This study tests whether a combination of tepotinib and ivonescimab is safe and helps people with MET exon 14–skipping non-small cell lung cancer.
-
Tepotinib versus standard treatments for advanced MET exon 14–mutated non-small cell lung cancer after prior therapy
This study will test whether tepotinib works better than standard chemotherapy choices for people with advanced non-small cell lung cancer that has a MET exon 14 mutation and whose disease progressed after at least one prior treatment.
-
Adding tepotinib to lazertinib for EGFR‑mutant metastatic lung cancer with MET overexpression or amplification after progression on lazertinib
This trial tests whether adding the MET blocker tepotinib to lazertinib helps people with EGFR‑mutant metastatic non‑small cell lung cancer whose tumors show MET overexpression or amplification and who have progressed on lazertinib.
-
Targeted treatment for advanced lung cancer with a specific gene change
This study is testing if a new lung cancer treatment called tepotinib, with or without another drug called ramucirumab, can help people with advanced non-small cell lung cancer that has a specific gene change.
Quick answers
How many clinical trials of Tepotinib are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (2 trials), South Korea (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 3: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.